News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Interim report first quarter 2016

April 29, 2016

PledPharma AB
Interim information

Interim report first quarter 2016

The projects are progressing according to plan

Stockholm, 2016-04-29 08:30 CEST (GLOBE NEWSWIRE) -- 
Quarter summary

·       Net result for the quarter amounted to SEK -6 846 (-12 163) k

·       Cash equivalents at the end of the quarter amounted to SEK 43 684 (86
318) k 

·       Cash flow from operating activities amounted to SEK -6 676 (-13 985) k

·       Result per share amounted to SEK -0.2 (-0.4)

Significant events during the quarter

·       No significant events to report for the period

Significant events after the end of the period

·       During the AGM the CEO reported that active discussions are being held
with a number of potential partners in the ongoing process of finding one or
more appropriate commercial partners for the continued development of PledOx®. 

·       The Annual General Meeting was held on April 14, 2016 where the General
Meeting resolved in accordance with the submitted proposals. As members of the
Board, Håkan Åström (Chairman), Andreas Bunge, Martin Nicklasson, Sten Nilsson
and Eva Redhe were elected. 

CEO comment

During the first quarter, our work has mainly focused on next step in the
PledOx project and we now have active discussions with a number of
pharmaceutical companies. 

The PledOx project, where we reported positive top-line results from the Phase
II study PLIANT in the spring of 2015, focuses on the development of a drug to
reduce the incidence of nerve damage associated with chemotherapy treatment of
colorectal cancer. 

The National Cancer Institute has published advice, for affected patients how
they can handle this type of very severe side-effects of chemotherapy. For
example, to ask for help when they will do so simple everyday tasks such as
buttoning buttons, use a computer or a pen. PledOx aims to solve these and
other significant problems for a large number of individuals. It is therefore
positive that the results we have obtained so far, shows a significant
reduction of this type of side effects. I look forward to additional follow-up
data, the so-called progression-free survival i.e., survival without tumor
growth, which we expect to report in the second quarter. 

During the quarter, we have also been working on our second project Aladote and
preparations for the start of a clinical trial. The drug candidate Aladote is
being developed with the aim to prevent acute liver damage associated with
acetaminophen overdose. The study is expected to start in late 2016. 

With robust clinical data, an approved composition of matter patent, valuable
information from this autumn's constructive meeting with the FDA, a strong team
and a significant commercial potential, we have a good basis for the remaining
development, partnership and commercialization of PledOx. 

PledPharma in brief

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially disabling and sometimes life-threatening condition that can be
caused by chemotherapy treatment and acetaminophen (paracetamol) poisoning. The
company's most advanced project PledOx® reduces nerve damage associated with
chemotherapy and positive 

results from the Phase IIb study PLIANT were presented during the spring of
2015. The drug candidate Aladote® is being developed to reduce the risk of
acute liver failure associated with acetaminophen poisoning. The project PP-099
seeks to limit the damage that occurs to the heart muscle during myocardial

PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the
company’s Certified Adviser (tel +46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10